GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (NAS:CSII) » Definitions » Cash Flow from Investing

Cardiovascular Systems (Cardiovascular Systems) Cash Flow from Investing : $21.5 Mil (TTM As of Dec. 2022)


View and export this data going back to 2006. Start your Free Trial

What is Cardiovascular Systems Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2022, Cardiovascular Systems spent $2.0 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $8.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $20.8 Mil on purchasing investments. It gained $29.9 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it received $0.0 Mil from other investing activities. In all, Cardiovascular Systems spent $0.9 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2022.


Cardiovascular Systems Cash Flow from Investing Historical Data

The historical data trend for Cardiovascular Systems's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiovascular Systems Cash Flow from Investing Chart

Cardiovascular Systems Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.10 -54.35 -8.67 -112.71 22.16

Cardiovascular Systems Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 3.38 7.68 11.34 -0.86

Cardiovascular Systems Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Cardiovascular Systems's Cash Flow from Investing for the fiscal year that ended in Jun. 2022 is calculated as:

Cardiovascular Systems's Cash Flow from Investing for the quarter that ended in Dec. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiovascular Systems  (NAS:CSII) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Cardiovascular Systems's purchase of property, plant, equipment for the three months ended in Dec. 2022 was $-2.0 Mil. It means Cardiovascular Systems spent $2.0 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Cardiovascular Systems's sale of property, plant, equipment for the three months ended in Dec. 2022 was $0.0 Mil. It means Cardiovascular Systems gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Cardiovascular Systems's purchase of business for the three months ended in Dec. 2022 was $-8.0 Mil. It means Cardiovascular Systems spent $8.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Cardiovascular Systems's sale of business for the three months ended in Dec. 2022 was $0.0 Mil. It means Cardiovascular Systems gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Cardiovascular Systems's purchase of investment for the three months ended in Dec. 2022 was $-20.8 Mil. It means Cardiovascular Systems spent {stock_data.stock.currency_symbol}}20.8 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Cardiovascular Systems's sale of investment for the three months ended in Dec. 2022 was $29.9 Mil. It means Cardiovascular Systems gained $29.9 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Cardiovascular Systems's net Intangibles purchase and sale for the three months ended in Dec. 2022 was $0.0 Mil. It means Cardiovascular Systems paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cardiovascular Systems's cash from discontinued investing activities for the three months ended in Dec. 2022 was 0.0 Mil. It means Cardiovascular Systems paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cardiovascular Systems's cash from other investing activities for the three months ended in Dec. 2022 was $0.0 Mil. It means Cardiovascular Systems received $0.0 Mil from other investing activities.


Cardiovascular Systems Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiovascular Systems (Cardiovascular Systems) Business Description

Traded in Other Exchanges
N/A
Address
1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416
Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.
Executives
Jeffrey S. Points officer: Chief Financial Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Scott R Ward director RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077
Erik Paulsen director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Rhonda J. Robb officer: Chief Operating Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Martha Goldberg Aronson director 40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Sachin H. Jain director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Alexander Rosenstein officer: General Counsel & Corp. Secy C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Sandra Sedo officer: Chief Compliance Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Kelvin K. Womack director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen J. Rempe officer: Chief Human Resources Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
John M. Hastings officer: VP Manufacturing & Operations C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen Stenbeck director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Ryan Egeland officer: VP of Medical Affairs C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
David Whitescarver officer: VP of Corp. Dev. & IP C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Laura Gillund officer: Chief Talent Officer